BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008. [PMID: 24142051 DOI: 10.1038/nbt.2725] [Cited by in Crossref: 130] [Cited by in F6Publishing: 121] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther 2015;22:391-403. [DOI: 10.1038/gt.2015.4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
2 Yang W, Zhou Z, Lau J, Hu S, Chen X. Functional T cell activation by smart nanosystems for effective cancer immunotherapy. Nano Today 2019;27:28-47. [DOI: 10.1016/j.nantod.2019.05.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
3 Watanabe K, Kuramitsu S, Posey AD Jr, June CH. Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. Front Immunol 2018;9:2486. [PMID: 30416506 DOI: 10.3389/fimmu.2018.02486] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 20.3] [Reference Citation Analysis]
4 Jena B, Moyes JS, Huls H, Cooper LJ. Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 2014;9:50-6. [PMID: 24488441 DOI: 10.1007/s11899-013-0197-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
5 Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res 2015;21:4431-9. [PMID: 26429982 DOI: 10.1158/1078-0432.CCR-14-3341] [Cited by in Crossref: 95] [Cited by in F6Publishing: 60] [Article Influence: 15.8] [Reference Citation Analysis]
6 Shi H, Yu F, Mao Y, Ju Q, Wu Y, Bai W, Wang P, Xu R, Jiang M, Shi J. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. J Thorac Dis 2018;10:2779-88. [PMID: 29997940 DOI: 10.21037/jtd.2018.04.91] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
7 Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood 2018;132:1134-45. [PMID: 30045840 DOI: 10.1182/blood-2017-08-802926] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
8 Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H, Fang W, Chen X, Zhang Y, Zou B, Li Q, Wan Y, Chen H, Tang Y, Zhao J, Weng D, Xia L, Zhang L, Xia J. Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. Clin Transl Immunology 2020;9:e1154. [PMID: 33072320 DOI: 10.1002/cti2.1154] [Reference Citation Analysis]
9 Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016;128:1688-700. [PMID: 27412889 DOI: 10.1182/blood-2016-04-711903] [Cited by in Crossref: 396] [Cited by in F6Publishing: 388] [Article Influence: 66.0] [Reference Citation Analysis]
10 Han A, Glanville J, Hansmann L, Davis MM. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol 2014;32:684-92. [PMID: 24952902 DOI: 10.1038/nbt.2938] [Cited by in Crossref: 305] [Cited by in F6Publishing: 266] [Article Influence: 38.1] [Reference Citation Analysis]
11 Marcinkowski B, Stevanović S, Helman SR, Norberg SM, Serna C, Jin B, Gkitsas N, Kadakia T, Warner A, Davis JL, Rooper L, Hinrichs CS. Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1. J Immunother Cancer 2019;7:229. [PMID: 31455429 DOI: 10.1186/s40425-019-0678-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
12 Guerrero AD, Moyes JS, Cooper LJ. The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer 2014;33:421-33. [PMID: 25189715 DOI: 10.5732/cjc.014.10100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
13 Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D. Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Rev Clin Immunol 2016;12:879-93. [PMID: 27070898 DOI: 10.1080/1744666X.2016.1176529] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bassan D, Gozlan YM, Sharbi-Yunger A, Tzehoval E, Eisenbach L. Optimizing T-cell receptor avidity with somatic hypermutation. Int J Cancer 2019;145:2816-26. [PMID: 31381134 DOI: 10.1002/ijc.32612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27297. [PMID: 24701370 DOI: 10.4161/onci.27297] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 10.5] [Reference Citation Analysis]
16 Fedorov VD, Sadelain M, Kloss CC. Novel approaches to enhance the specificity and safety of engineered T cells. Cancer J 2014;20:160-5. [PMID: 24667964 DOI: 10.1097/PPO.0000000000000040] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
17 Omokoko T, Simon P, Türeci Ö, Sahin U. Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies. Oncoimmunology 2015;4:e1005523. [PMID: 26140230 DOI: 10.1080/2162402X.2015.1005523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Shraibman B, Kadosh DM, Barnea E, Admon A. Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. Mol Cell Proteomics 2016;15:3058-70. [PMID: 27412690 DOI: 10.1074/mcp.M116.060350] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
19 Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J 2014;20:151-5. [PMID: 24667962 DOI: 10.1097/PPO.0000000000000032] [Cited by in Crossref: 123] [Cited by in F6Publishing: 77] [Article Influence: 15.4] [Reference Citation Analysis]
20 Ando M, Nakauchi H. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes. Exp Hematol 2017;47:2-12. [PMID: 27826124 DOI: 10.1016/j.exphem.2016.10.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kulemzin SV, Kuznetsova VV, Mamonkin M, Taranin AV, Gorchakov AA. CAR T-cell therapy: Balance of efficacy and safety. Mol Biol 2017;51:237-50. [DOI: 10.1134/s0026893317020145] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Baxter D, Ullman CG, Mason JM. Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions. Future Med Chem 2014;6:2073-92. [PMID: 25531969 DOI: 10.4155/fmc.14.134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhao L, Liu Y, Zhao F, Jin Y, Feng J, Geng R, Sun J, Kang L, Yu L, Wei Y. Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. Mol Ther Oncolytics 2020;16:262-71. [PMID: 32181327 DOI: 10.1016/j.omto.2020.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 Ochi T, Nakatsugawa M, Chamoto K, Tanaka S, Yamashita Y, Guo T, Fujiwara H, Yasukawa M, Butler MO, Hirano N. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. Cancer Immunol Res 2015;3:1070-81. [PMID: 25943533 DOI: 10.1158/2326-6066.CIR-14-0222] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
25 Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol 2017;12:1798-805. [PMID: 28939128 DOI: 10.1016/j.jtho.2017.08.022] [Cited by in Crossref: 184] [Cited by in F6Publishing: 195] [Article Influence: 36.8] [Reference Citation Analysis]
26 Luo C, Wei J, Han W. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. Sci China Life Sci 2016;59:349-59. [PMID: 27009301 DOI: 10.1007/s11427-016-5034-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
27 Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Front Immunol 2017;8:1850. [PMID: 29312333 DOI: 10.3389/fimmu.2017.01850] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 18.6] [Reference Citation Analysis]
28 Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22:26-36. [PMID: 26735408 DOI: 10.1038/nm.4015] [Cited by in Crossref: 216] [Cited by in F6Publishing: 206] [Article Influence: 36.0] [Reference Citation Analysis]
29 Sadelain M. Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol 2016;41:68-76. [PMID: 27372731 DOI: 10.1016/j.coi.2016.06.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
30 Ho P, Ede C, Chen YY. Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity. ACS Synth Biol 2017;6:1484-95. [PMID: 28510446 DOI: 10.1021/acssynbio.6b00392] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
31 Lu L, Xing K, Wei W, Ling Y, Li P, Li S, Wang Y, Xie D, Guo R, Cai M. Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma. Int J Cancer 2021. [PMID: 33890283 DOI: 10.1002/ijc.33609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Karpanen T, Olweus J. T-cell receptor gene therapy--ready to go viral? Mol Oncol 2015;9:2019-42. [PMID: 26548533 DOI: 10.1016/j.molonc.2015.10.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
33 Chen L, Qiao D, Wang J, Tian G, Wang M. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers. Immunol Lett 2019;216:51-62. [PMID: 31597088 DOI: 10.1016/j.imlet.2019.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
34 Maruta M, Ochi T, Tanimoto K, Asai H, Saitou T, Fujiwara H, Imamura T, Takenaka K, Yasukawa M. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy. Sci Rep 2019;9:13293. [PMID: 31527633 DOI: 10.1038/s41598-019-49834-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
35 Chen L, Chen F, Li J, Pu Y, Yang C, Wang Y, Lei Y, Huang Y. CAR-T cell therapy for lung cancer: Potential and perspective. Thorac Cancer 2022. [PMID: 35289077 DOI: 10.1111/1759-7714.14375] [Reference Citation Analysis]
36 Dudaniec K, Westendorf K, Nössner E, Uckert W. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy. Hum Gene Ther 2021. [PMID: 33798008 DOI: 10.1089/hum.2020.283] [Reference Citation Analysis]
37 Sun Z, Chen F, Meng F, Wei J, Liu B. MHC class II restricted neoantigen: A promising target in tumor immunotherapy. Cancer Letters 2017;392:17-25. [DOI: 10.1016/j.canlet.2016.12.039] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
38 van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J Clin Invest 2019;129:774-85. [PMID: 30640174 DOI: 10.1172/JCI97482] [Cited by in Crossref: 67] [Cited by in F6Publishing: 41] [Article Influence: 22.3] [Reference Citation Analysis]
39 Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. J Clin Oncol 2019;37:2759-68. [PMID: 31408414 DOI: 10.1200/JCO.18.02424] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 18.7] [Reference Citation Analysis]
40 Blankenstein T. Receptor combinations hone T-cell therapy. Nat Biotechnol 2016;34:389-91. [PMID: 27054992 DOI: 10.1038/nbt.3539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. Mol Ther 2021;29:1199-213. [PMID: 33212301 DOI: 10.1016/j.ymthe.2020.11.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Greco R, Oliveira G, Stanghellini MT, Vago L, Bondanza A, Peccatori J, Cieri N, Marktel S, Mastaglio S, Bordignon C, Bonini C, Ciceri F. Improving the safety of cell therapy with the TK-suicide gene. Front Pharmacol 2015;6:95. [PMID: 25999859 DOI: 10.3389/fphar.2015.00095] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 9.6] [Reference Citation Analysis]
43 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, Bawden E, Hinze D, van den Boorn-konijnenberg D, Daoud M, Aymans P, Landsberg J, Smyth MJ, Flatz L, Tüting T, Bald T, Gebhardt T, Hölzel M. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity 2020;53:564-580.e9. [DOI: 10.1016/j.immuni.2020.07.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
45 Dhanik A, Kirshner JR, MacDonald D, Thurston G, Lin HC, Murphy AJ, Zhang W. In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy. BMC Bioinformatics 2016;17:286. [PMID: 27439771 DOI: 10.1186/s12859-016-1150-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
46 Darowski D, Kobold S, Jost C, Klein C. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. MAbs 2019;11:621-31. [PMID: 30892136 DOI: 10.1080/19420862.2019.1596511] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
47 Chen LC, Chen YY. Outsmarting and outmuscling cancer cells with synthetic and systems immunology. Curr Opin Biotechnol 2019;60:111-8. [PMID: 30822698 DOI: 10.1016/j.copbio.2019.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
48 Wijetunga NA, Yu Y, Morris LG, Lee N, Riaz N. The head and neck cancer genome in the era of immunotherapy. Oral Oncol 2021;112:105040. [PMID: 33197752 DOI: 10.1016/j.oraloncology.2020.105040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
49 Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology 2016;5:e1227897. [PMID: 27853651 DOI: 10.1080/2162402X.2016.1227897] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
50 Gattinoni L. Adoptive T cell transfer: Imagining the next generation of cancer immunotherapies. Semin Immunol 2016;28:1-2. [PMID: 27161516 DOI: 10.1016/j.smim.2016.03.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
51 Rivière I, Sadelain M. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther 2017;25:1117-24. [PMID: 28456379 DOI: 10.1016/j.ymthe.2017.03.034] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 12.8] [Reference Citation Analysis]
52 Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu YS, Min IM, Jin MM. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep 2017;7:14366. [PMID: 29085043 DOI: 10.1038/s41598-017-14749-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
53 Tomei S, Wang E, Delogu LG, Marincola FM, Bedognetti D. Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opinion on Biological Therapy 2014;14:663-86. [DOI: 10.1517/14712598.2014.890586] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
54 Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 2019;120:26-37. [PMID: 30413825 DOI: 10.1038/s41416-018-0325-1] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 20.3] [Reference Citation Analysis]
55 Laumont CM, Daouda T, Laverdure JP, Bonneil É, Caron-Lizotte O, Hardy MP, Granados DP, Durette C, Lemieux S, Thibault P, Perreault C. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat Commun 2016;7:10238. [PMID: 26728094 DOI: 10.1038/ncomms10238] [Cited by in Crossref: 113] [Cited by in F6Publishing: 95] [Article Influence: 18.8] [Reference Citation Analysis]
56 Blankenstein T, Leisegang M, Uckert W, Schreiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015;33:112-119. [PMID: 25728991 DOI: 10.1016/j.coi.2015.02.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
57 Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, Zhou L, Loew A, Young RM, June CH, Zhao Y. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 2015;75:3596-607. [PMID: 26330166 DOI: 10.1158/0008-5472.CAN-15-0159] [Cited by in Crossref: 251] [Cited by in F6Publishing: 162] [Article Influence: 35.9] [Reference Citation Analysis]
58 Sadozai H, Gruber T, Hunger RE, Schenk M. Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Front Immunol 2017;8:1617. [PMID: 29276510 DOI: 10.3389/fimmu.2017.01617] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
59 Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer 2019;7:258. [PMID: 31619289 DOI: 10.1186/s40425-019-0741-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
60 Sood AK, Nemeth M, Wang J, Wu Y, Gandhi S. Opportunities for Antigen Discovery in Metastatic Breast Cancer. Front Immunol 2020;11:570049. [PMID: 33193348 DOI: 10.3389/fimmu.2020.570049] [Reference Citation Analysis]
61 Granados DP, Laumont CM, Thibault P, Perreault C. The nature of self for T cells-a systems-level perspective. Curr Opin Immunol 2015;34:1-8. [PMID: 25466393 DOI: 10.1016/j.coi.2014.10.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
62 Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanović S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med 2021;27:419-25. [PMID: 33558725 DOI: 10.1038/s41591-020-01225-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
63 Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv 2021;7:eabi5781. [PMID: 34108220 DOI: 10.1126/sciadv.abi5781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, Fraietta JA. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Front Immunol. 2018;9:2740. [PMID: 30559740 DOI: 10.3389/fimmu.2018.02740] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
65 Brennan FR, Baumann A, Blaich G, de Haan L, Fagg R, Kiessling A, Kronenberg S, Locher M, Milton M, Tibbitts J, Ulrich P, Weir L. Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies. Regul Toxicol Pharmacol 2015;73:265-75. [PMID: 26219199 DOI: 10.1016/j.yrtph.2015.07.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
66 Phoon YP, Tannenbaum C, Diaz-Montero CM. Immunobiology of Melanoma. Clin Plast Surg 2021;48:561-76. [PMID: 34503717 DOI: 10.1016/j.cps.2021.06.005] [Reference Citation Analysis]
67 Saleh OM, Albakri KA, Alabdallat YJ, Dajani MH, El Gazzar WB. The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers 2021;:1-13. [PMID: 34882051 DOI: 10.1080/1354750X.2021.2016973] [Reference Citation Analysis]
68 Motofei IG. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. Expert Opin Drug Saf 2021;:1-14. [PMID: 34937484 DOI: 10.1080/14740338.2022.2020243] [Reference Citation Analysis]
69 Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015;33:1543-50. [PMID: 25823737 DOI: 10.1200/JCO.2014.58.9093] [Cited by in Crossref: 298] [Cited by in F6Publishing: 177] [Article Influence: 42.6] [Reference Citation Analysis]
70 Chang ZL, Chen YY. CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med 2017;23:430-50. [PMID: 28416139 DOI: 10.1016/j.molmed.2017.03.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 11.2] [Reference Citation Analysis]
71 Dharmasiri U, Isenberg SL, Glish GL, Armistead PM. Differential ion mobility spectrometry coupled to tandem mass spectrometry enables targeted leukemia antigen detection. J Proteome Res 2014;13:4356-62. [PMID: 25184817 DOI: 10.1021/pr500527c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
72 Padda J, Khalid K, Zubair U, Peethala MM, Kakani V, Goriparthi L, Almanie AH, Cooper AC, Jean-Charles G. Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma. Cureus 2021;13:e15917. [PMID: 34322356 DOI: 10.7759/cureus.15917] [Reference Citation Analysis]
73 Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016;5:e1231292. [PMID: 27999741 DOI: 10.1080/2162402X.2016.1231292] [Cited by in Crossref: 58] [Cited by in F6Publishing: 38] [Article Influence: 9.7] [Reference Citation Analysis]
74 Geiger M, Stubenrauch KG, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, Lauer ME, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein C. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nat Commun 2020;11:3196. [PMID: 32581215 DOI: 10.1038/s41467-020-16838-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
75 Chen Q, Hu Q, Dukhovlinova E, Chen G, Ahn S, Wang C, Ogunnaike EA, Ligler FS, Dotti G, Gu Z. Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells. Adv Mater 2019;31:e1900192. [PMID: 30916367 DOI: 10.1002/adma.201900192] [Cited by in Crossref: 116] [Cited by in F6Publishing: 119] [Article Influence: 38.7] [Reference Citation Analysis]
76 Ouchi Y, Patil A, Tamura Y, Nishimasu H, Negishi A, Paul SK, Takemura N, Satoh T, Kimura Y, Kurachi M, Nureki O, Nakai K, Kiyono H, Uematsu S. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing. Int Immunol 2018;30:141-54. [PMID: 29617862 DOI: 10.1093/intimm/dxy006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
77 Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017;27:11-37. [PMID: 28025978 DOI: 10.1038/cr.2016.155] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 19.3] [Reference Citation Analysis]
78 Bluhm J, Kieback E, Marino SF, Oden F, Westermann J, Chmielewski M, Abken H, Uckert W, Höpken UE, Rehm A. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. Mol Ther 2018;26:1906-20. [PMID: 30078440 DOI: 10.1016/j.ymthe.2018.06.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
79 Azad TD, Razavi SM, Jin B, Lee K, Li G. Glioblastoma antigen discovery--foundations for immunotherapy. J Neurooncol 2015;123:347-58. [PMID: 26045361 DOI: 10.1007/s11060-015-1836-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
80 Ahmed KK, Geary SM, Salem AK. Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines. J Control Release 2017;248:1-9. [PMID: 28057523 DOI: 10.1016/j.jconrel.2016.12.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
81 Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Front Immunol 2018;9:239. [PMID: 29515572 DOI: 10.3389/fimmu.2018.00239] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
82 Yu YD, Kim TJ. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review. Int J Mol Sci 2021;22:E640. [PMID: 33440664 DOI: 10.3390/ijms22020640] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Chu F, Cao J, Neelalpu SS. Versatile CAR T-cells for cancer immunotherapy. Contemp Oncol (Pozn) 2018;22:73-80. [PMID: 29628798 DOI: 10.5114/wo.2018.73892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
84 Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. Cancer Immunol Res 2018;6:605-16. [PMID: 29588319 DOI: 10.1158/2326-6066.CIR-17-0314] [Cited by in Crossref: 105] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
85 Liu Q, Fang Z, Liu M, Xu R, Yi F, Wei Y, Zeng L, Zhang W. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials. J Clin Pharm Ther 2021. [PMID: 34101874 DOI: 10.1111/jcpt.13465] [Reference Citation Analysis]
86 Chen GM, Azzam A, Ding YY, Barrett DM, Grupp SA, Tan K. Dissecting the Tumor-Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. Clin Cancer Res 2020;26:3505-13. [PMID: 32127393 DOI: 10.1158/1078-0432.CCR-19-3888] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
87 Leclercq G, Haegel H, Schneider A, Giusti AM, Marrer-Berger E, Boetsch C, Walz AC, Pulko V, Sam J, Challier J, Ferlini C, Odermatt A, Umaña P, Bacac M, Klein C. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. J Immunother Cancer 2021;9:e002582. [PMID: 34326166 DOI: 10.1136/jitc-2021-002582] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 Gardeck AM, Sheehan J, Low WC. Immune and viral therapies for malignant primary brain tumors. Expert Opinion on Biological Therapy 2017;17:457-74. [DOI: 10.1080/14712598.2017.1296132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
89 Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight 2018;3:99488. [PMID: 29669936 DOI: 10.1172/jci.insight.99488] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
90 Siddiqui RS, Sardar M. A Systematic Review of the Role of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in the Treatment of Solid Tumors. Cureus 2021;13:e14494. [PMID: 34007747 DOI: 10.7759/cureus.14494] [Reference Citation Analysis]
91 Nemec PS, Kapatos A, Holmes JC, Stowe DM, Hess PR. Cancer-testis antigens in canine histiocytic sarcoma and other malignancies. Vet Comp Oncol 2019;17:317-28. [PMID: 30854786 DOI: 10.1111/vco.12475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
92 Zhang J, Yu M, Li X, Huang X, Wang H. Combination therapy improves immune response and prognosis in patients with advanced oral mucosal melanoma: A clinical treatment success. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;126:307-16. [PMID: 29958936 DOI: 10.1016/j.oooo.2018.05.004] [Reference Citation Analysis]
93 Zhao L, Li J, Liu Y, Kang L, Chen H, Jin Y, Zhao F, Feng J, Fang C, Zhu B, Ding S, Yu L, Wei Y, Zhou J. Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells. J Immunother 2018;41:45-52. [PMID: 29252915 DOI: 10.1097/CJI.0000000000000207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
94 Kaufmann J, Wentzensen N, Brinker TJ, Grabe N. Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. Oncotarget 2019;10:2515-29. [PMID: 31069014 DOI: 10.18632/oncotarget.26808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
95 Chakravarti D, Wong WW. Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol 2015;33:449-61. [PMID: 26088008 DOI: 10.1016/j.tibtech.2015.05.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
96 Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature 2017;545:423-31. [PMID: 28541315 DOI: 10.1038/nature22395] [Cited by in Crossref: 359] [Cited by in F6Publishing: 332] [Article Influence: 71.8] [Reference Citation Analysis]
97 Geering B, Fussenegger M. Synthetic immunology: modulating the human immune system. Trends in Biotechnology 2015;33:65-79. [DOI: 10.1016/j.tibtech.2014.10.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
98 Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer 2020;140:59-64. [PMID: 31881412 DOI: 10.1016/j.lungcan.2019.12.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
99 Li J, Wang Y, Liang R, An X, Wang K, Shen G, Tu Y, Zhu J, Tao J. Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine 2015;11:769-94. [PMID: 25555352 DOI: 10.1016/j.nano.2014.11.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
100 Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, Nakauchi H, Ando M. Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing. Cells 2022;11:269. [DOI: 10.3390/cells11020269] [Reference Citation Analysis]
101 Lee CH, Salio M, Napolitani G, Ogg G, Simmons A, Koohy H. Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors. Front Immunol 2020;11:565096. [PMID: 33193332 DOI: 10.3389/fimmu.2020.565096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Kimura H, Araya T, Yoneda T, Shirasaki H, Kurokawa K, Sakai T, Koba H, Tambo Y, Nishikawa S, Sone T, Kasahara K. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun (Lond) 2019;39:78. [PMID: 31753015 DOI: 10.1186/s40880-019-0423-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, von Pein U, Koch-nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M. A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma. Blood 2016;127:3202-14. [DOI: 10.1182/blood-2015-10-676536] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
104 Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov 2021;20:531-50. [PMID: 33972771 DOI: 10.1038/s41573-021-00189-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
105 Wu J, Chen Z, Wickström SL, Gao J, He X, Jing X, Wu J, Du Q, Yang M, Chen Y, Zhang D, Yin X, Guo Z, Jensen L, Yang Y, Tao W, Lundqvist A, Kiessling R, Cao Y. Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism. Adv Sci (Weinh) 2021;8:e2101029. [PMID: 34486239 DOI: 10.1002/advs.202101029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Chen W, Chen Q, Chen Q, Cui C, Duan S, Kang Y, Liu Y, Liu Y, Muhammad W, Shao S, Tang C, Wang J, Wang L, Xiong M, Yin L, Zhang K, Zhang Z, Zhen X, Feng J, Gao C, Gu Z, He C, Ji J, Jiang X, Liu W, Liu Z, Peng H, Shen Y, Shi L, Sun X, Wang H, Wang J, Xiao H, Xu F, Zhong Z, Zhang X, Chen X. Biomedical polymers: synthesis, properties, and applications. Sci China Chem . [DOI: 10.1007/s11426-022-1243-5] [Reference Citation Analysis]
107 Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S. Human c-SRC kinase (CSK) overexpression makes T cells dummy. Cancer Immunol Immunother 2018;67:525-36. [PMID: 29248956 DOI: 10.1007/s00262-017-2105-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
108 Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncolytics 2016;3:1-9. [PMID: 29675462 DOI: 10.1038/mto.2016.23] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
109 Yang Y, Sun X, Xu J, Cui C, Safari Yazd H, Pan X, Zhu Y, Chen X, Li X, Li J, Tan W. Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy. ACS Nano 2020;14:9562-71. [DOI: 10.1021/acsnano.9b09884] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
110 Yang X, Xie S, Yang X, Cueva JC, Hou X, Tang Z, Yao H, Mo F, Yin S, Liu A, Lu X. Opportunities and Challenges for Antibodies against Intracellular Antigens. Theranostics 2019;9:7792-806. [PMID: 31695801 DOI: 10.7150/thno.35486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
111 Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, Powell DJ Jr. High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 2016;30:1355-64. [PMID: 26898190 DOI: 10.1038/leu.2016.35] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
112 Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, Arina A, Duraiswamy J, Weichselbaum RR, Uckert W, Nakamura Y, Schreiber H. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res 2016;22:2734-43. [PMID: 26667491 DOI: 10.1158/1078-0432.CCR-15-2361] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
113 Smith TW Jr, Nishimura MI. Targeting Cancer with Genetically Engineered TCR T Cells. Recent Results Cancer Res 2020;214:129-51. [PMID: 31473851 DOI: 10.1007/978-3-030-23765-3_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
114 Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P, Bacac M. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. Front Oncol 2020;10:575737. [PMID: 33330050 DOI: 10.3389/fonc.2020.575737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
115 Schooten E, Di Maggio A, van Bergen en Henegouwen PM, Kijanka MM. MAGE-A antigens as targets for cancer immunotherapy. Cancer Treatment Reviews 2018;67:54-62. [DOI: 10.1016/j.ctrv.2018.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
116 Huang Y, Mao Q, He J, Su J, Peng Y, Liang W, Hu Z, Zhou S, Lu X, Zhao Y. Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity. Sci Rep. 2017;7:46544. [PMID: 28436481 DOI: 10.1038/srep46544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
117 Chen Y, Ju L, Rushdi M, Ge C, Zhu C. Receptor-mediated cell mechanosensing. Mol Biol Cell 2017;28:3134-55. [PMID: 28954860 DOI: 10.1091/mbc.E17-04-0228] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 16.8] [Reference Citation Analysis]
118 Dutoit V, Migliorini D, Dietrich PY, Walker PR. Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front Oncol 2016;6:256. [PMID: 28003994 DOI: 10.3389/fonc.2016.00256] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
119 Chakravarti D, Caraballo LD, Weinberg BH, Wong WW. Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy. ACS Synth Biol 2019;8:1744-54. [PMID: 31268301 DOI: 10.1021/acssynbio.8b00512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
120 Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol 2015;27:466-74. [PMID: 26352543 DOI: 10.1097/CCO.0000000000000232] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
121 Norberg SM, Hinrichs CS. Advances in Adoptive Cell Therapy for Head and Neck Cancer. Otolaryngol Clin North Am 2021;54:761-8. [PMID: 34116844 DOI: 10.1016/j.otc.2021.05.001] [Reference Citation Analysis]
122 Zhylko A, Winiarska M, Graczyk-Jarzynka A. The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. Cancers (Basel) 2020;12:E2030. [PMID: 32722109 DOI: 10.3390/cancers12082030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
123 Wang SS, Luong K, Gracey FM, Jabar S, McColl B, Cross RS, Jenkins MR. A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse. Biomedicines 2021;9:1875. [PMID: 34944696 DOI: 10.3390/biomedicines9121875] [Reference Citation Analysis]
124 Erfanian N, Derakhshani A, Nasseri S, Fereidouni M, Baradaran B, Jalili Tabrizi N, Brunetti O, Bernardini R, Silvestris N, Safarpour H. Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. Biomed Pharmacother 2021;146:112558. [PMID: 34953396 DOI: 10.1016/j.biopha.2021.112558] [Reference Citation Analysis]
125 Chen J, Liu Z, Wang K, Jiang C, Zhang C, Wang B. A calibration-free method for biosensing in cell manufacturing. IISE Transactions. [DOI: 10.1080/24725854.2020.1856982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Antonia SJ, Vansteenkiste JF, Moon E. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. Am Soc Clin Oncol Educ Book 2016;35:e450-8. [PMID: 27249753 DOI: 10.1200/EDBK_158712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
127 Hinrichs CS. Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. Clin Cancer Res 2016;22:1559-64. [PMID: 27037253 DOI: 10.1158/1078-0432.CCR-15-1294] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
128 Munisvaradass R, Kumar S, Govindasamy C, Alnumair KS, Mok PL. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells. Int J Mol Sci 2017;18:E1797. [PMID: 28885562 DOI: 10.3390/ijms18091797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
129 Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G, Schachter J, Itzhaki O, Besser MJ. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother 2018;67:1221-30. [PMID: 29845338 DOI: 10.1007/s00262-018-2174-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
130 Owens GL, Sheard VE, Kalaitsidou M, Blount D, Lad Y, Cheadle EJ, Edmondson RJ, Kooner G, Gilham DE, Harrop R. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer. J Immunother 2018;41:130-40. [PMID: 29239915 DOI: 10.1097/CJI.0000000000000203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
131 Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, Sam J, Pulko V, Schneider A, Giusti AM, Challier J, Freimoser-grundschober A, Larivière L, Odermatt A, Stern M, Umana P, Bacac M, Klein C. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J Immunother Cancer 2022;10:e003766. [DOI: 10.1136/jitc-2021-003766] [Reference Citation Analysis]